Luomalla maksuttoman Inderes-tilin, pääset käsiksi Inderesin analyysiin, voit tilata suositun aamukatsauksen ja seurata sinua kiinnostavia yhtiöitä sekä keskusteluita.
Onko sinulla jo Inderes-tili?
Follow this company like 250 other investors.
Research
Ascelia Pharma AB (publ) (ticker: ACE), today presented updates on expected mid-2023 SPARKLE Phase 3 readout, as well as the launch strategy to address the 800 million USD global market opportunity with 100,000 procedures in the target patient population in the US alone. Investors, analysts, and media are invited to join today’s Investor Update with a live Q&A webcast at 14:00 CET.
Ascelia Pharma AB (publ) (ticker: ACE) announced today that René Spogárd, a member of the Ascelia Pharma AB Board of Directors, has passed away.
René Spogárd has been a director of Ascelia Pharma since June 2017.
Ascelia Pharma AB (publ) (ticker: ACE) announced today the decision of the US Patent and Trademark Office (USPTO) to allow the issuance of a third patent covering the composition of Oncoral.
Ascelia Pharma AB (publ) (ticker: ACE), hereby invites analysts, investors and media to its investor update on Tuesday March 14, 2023 at 14:00. Focus of the event will be on bringing Orviglance to market – next steps towards launch.
Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that the Last Patient Last Visit (LPLV) has now been completed and 85 patients in total have successfully completed the pivotal phase 3 clinical study SPARKLE with the lead candidate drug Orviglance®.
During the month of February, the number of shares and votes in Ascelia Pharma AB have changed due to conversion of a total of 54,500 series C shares into a total of 54,500 ordinary shares for delivery of shares to participants in the performance-based share saving program that was adopted by the annual general meeting held on 14 November 2019 (LTI 2019).
Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced the successful completion of the patient enrollment in the company’s pivotal phase 3 clinical study SPARKLE with the lead candidate drug Orviglance®.
The board of directors of Ascelia Pharma AB (“Ascelia”) has on February 21, 2023 resolved to convert 54,500 series C shares into ordinary shares for delivery of shares to participants in the long-term incentive program in the form of a performance-based share saving program that was adopted at the annual general meeting held on 14 November 2019 (“LTI 2019”).
Ascelia Pharma AB (publ) (ticker: ACE) today published its Q4 financial report for 2022 (January – December 2022), which is now available on the company’s website:
https://www.ascelia.com/ir-media/financial-reports/
SIGNIFICANT EVENTS IN Q4 2022
Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that by January 27, 2023, 71 patients have completed the pivotal Phase 3 clinical SPARKLE study with the lead candidate drug Orviglance.
